Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)

Annane, Djillali; Mira, Jean Paul; Ware, Lorraine B; Gordon, Anthony C; Sevransky, Jonathan; Stüber, Frank; Heagerty, Patrick J; Wellman, Hugh F; Neira, Mauricio; Mancini, Alexandra Dj; Russell, James A (2012). Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated). Annals of intensive care, 2(1), p. 15. Heidelberg: Springer 10.1186/2110-5820-2-15

Full text not available from this repository.

A genomic biomarker identifying patients likely to benefit from drotrecogin alfa (activated) (DAA) may be clinically useful as a companion diagnostic. This trial was designed to validate biomarkers (improved response polymorphisms (IRPs)). Each IRP (A and B) contains two single nucleotide polymorphisms that were associated with a differential DAA treatment effect.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic and Policlinic for Anaesthesiology and Pain Therapy
UniBE Contributor:	Stüber, Frank
ISSN:	2110-5820
Publisher:	Springer
Language:	English
Submitter:	Jeannie Wurz
Date Deposited:	04 Oct 2013 14:33
Last Modified:	05 Dec 2022 14:10
Publisher DOI:	10.1186/2110-5820-2-15
PubMed ID:	22694772
URI:	https://boris.unibe.ch/id/eprint/13016 (FactScience: 219517)